Company intelligence / Profile preview

Yabao Pharmaceutical Group Co., Ltd.

Yuncheng, Shanxi, Chinapharmacompass.com ↗

Ownership: Private
Employees: ~5600
Development stage: Commercial

Overview

The company has multiple approved products including Chlorquinaldol for Acne Vulgaris and Povidone-Iodine for Vulvovaginal Candidiasis. They also have several products in clinical development, including Phase 3 Neiyi Tongjing Granules for Dysmenorrhea, Phase 2 Xingshen Huayu Dropping Pills for Acute Ischemic Stroke, and Phase 2 Recombinant human annexin 5 protein for Sepsis.

Therapeutic areas: Infectious DiseasesEndocrinologyDermatologyNeurologyWomen's Health
Modalities: Small molecule drugsHerbal medicineBispecific antibodyFusion protein
Industry: Biotech

Drug pipeline

18 assets

globalagliatin

17 more assets in the full pipeline.

Request access →

Partnerships

Eli Lilly and CompanySciecure Pharma

Beyond the preview

Go deeper on Yabao Pharmaceutical Group Co., Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Yabao Pharmaceutical Group Co., Ltd..

Explore the full profile